抑郁与焦虑和癌症发病及死亡风险的队列研究系统综述与meta分析
结果显示抑郁和焦虑与癌症发病风险(校正RR 1.13,95%CI 1.06-1.19)、癌症特异性死亡(1.21,1.16-1.26)及癌症患者全因死亡(1.24,1.13-1.35)显著升高相关;临床诊断的抑郁焦虑与更高的癌症发病、更差的癌症生存和更高的癌症特异性死亡相关,而心理困扰(抑郁焦虑症状)仅与更高的癌症特异性死亡和更差的癌症生存相关,与癌症发病无关。
要点
- 抑郁和焦虑与癌症发病、癌症特异性死亡及癌症患者全因死亡风险显著升高相关。
- 临床诊断的抑郁焦虑与更高的癌症发病、更差的癌症生存和更高的癌症特异性死亡相关。
- 心理困扰(抑郁焦虑症状)与更高的癌症特异性死亡和更差的癌症生存相关,但与癌症发病无关。
核心结论
- 抑郁和焦虑可能对癌症具有病因学作用和预后影响,但存在潜在反向因果,且研究间异质性较大,结果需谨慎解读。
- 对癌症患者和一般人群早期识别并有效干预抑郁和焦虑具有公共卫生和临床重要性。
研究设计与样本
- 采用随机效应或固定效应模型(视情况而定)合并癌症发病和死亡的相对风险(RR)估计值。
- 按不同研究和参与者特征分层进行亚组分析。
主要发现
- 总体抑郁和焦虑与癌症发病风险显著升高相关(校正RR 1.13,95%CI 1.06-1.19)。
- 总体抑郁和焦虑与癌症特异性死亡风险显著升高相关(RR 1.21,95%CI 1.16-1.26)。
- 总体抑郁和焦虑与癌症患者全因死亡风险显著升高相关(RR 1.24,95%CI 1.13-1.35)。
- 抑郁和焦虑相关的估计绝对风险增加(ARI)为癌症发病34.3例/100,000人年(15.8-50.2),癌症特异性死亡28.2例/100,000人年(21.5-34.9)。
- 部位特异性分析显示抑郁和焦虑与肺癌、口腔癌、前列腺癌和皮肤癌的发病风险升高相关,与肺癌、膀胱癌、乳腺癌、结直肠癌、造血系统肿瘤、肾癌和前列腺癌的癌症特异性死亡风险升高相关,与肺癌患者全因死亡风险升高相关。
关键数值与推荐
- 临床诊断的抑郁和焦虑与更高的癌症发病、更差的癌症生存和更高的癌症特异性死亡相关。
- 心理困扰(抑郁和焦虑症状)与更高的癌症特异性死亡和更差的癌症生存相关,但与癌症发病增加无关。
临床怎么用
- 在癌症患者和一般人群中早期识别并有效干预抑郁和焦虑具有公共卫生和临床重要性。
- 临床诊断的抑郁焦虑可能提示更高的癌症发病和更差的癌症预后,需关注此类人群的癌症筛查和监测。
局限性
- 存在潜在反向因果。
- 纳入研究间存在 substantial 异质性,结果应谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The link between depression and anxiety status and cancer outcomes has been well-documented but remains unclear. We comprehensively quantified the association between depression and anxiety defined by symptom scales or clinical diagnosis and the risk of cancer incidence, cancer-specific mortality, and all-cause mortality in cancer patients. Pooled estimates of the relative risks (RRs) for cancer incidence and mortality were performed in a meta-analysis by random effects or fixed effects models as appropriate. Associations were tested in subgroups stratified by different study and participant characteristics. Fifty-one eligible cohort studies involving 2,611,907 participants with a mean follow-up period of 10.3 years were identified. Overall, depression and anxiety were associated with a significantly increased risk of cancer incidence (adjusted RR: 1.13, 95% CI: 1.06-1.19), cancer-specific mortality (1.21, 1.16-1.26), and all-cause mortality in cancer patients (1.24, 1.13-1.35). The estimated absolute risk increases (ARIs) associated with depression and anxiety were 34.3 events/100,000 person years (15.8-50.2) for cancer incidence and 28.2 events/100,000 person years (21.5-34.9) for cancer-specific mortality. Subgroup analyses demonstrated that clinically diagnosed depression and anxiety were related to higher cancer incidence, poorer cancer survival, and higher cancer-specific mortality. Psychological distress (symptoms of depression and anxiety) was related to higher cancer-specific mortality and poorer cancer survival but not to increased cancer incidence. Site-specific analyses indicated that overall, depression and anxiety were associated with an increased incidence risks for cancers of the lung, oral cavity, prostate and skin, a higher cancer-specific mortality risk for cancers of the lung, bladder, breast, colorectum, hematopoietic system, kidney and prostate, and an increased all-cause mortality risk in lung cancer patients. These analyses suggest that depression and anxiety may have an etiologic role and prognostic impact on cancer, although there is potential reverse causality; Furthermore, there was substantial heterogeneity among the included studies, and the results should be interpreted with caution. Early detection and effective intervention of depression and anxiety in cancer patients and the general population have public health and clinical importance.
引用
- Wang YH, Li JQ, Shi JF, et al. Depression and anxiety in relation to cancer incidence and mortality: a systematic review and meta-analysis of cohort studies. Mol Psychiatry. 2019. PMID: 31745237. doi:10.1038/s41380-019-0595-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。